SESSION I:
BIOMARKER AND BIOSIGNATURE PRINCIPLES

8:40 a.m.

Workshop Objective: What parameters should be considered when developing a high-impact biomarker?

 

DENNIS CHOI, Workshop Chair

Professor of Pharmacology and Experimental Therapeutics

Boston University

8:50 a.m.

Introduction to the fNIH Biomarkers Consortium

 

TOM INSEL

Director

National Institute of Mental Health

9:10 a.m.

Lessons Learned from Alzheimer’s Disease and the NIA Alzheimer’s Disease Neuroimaging Initiative

 

WILLIAM POTTER

Vice President

Merck Research Laboratories

Clinical Neuroscience

SESSION II:
POTENTIAL TOOLS FOR BIOMARKER AND BIOSIGNATURE DEVELOPMENT

Session Objective: Discuss which tools and parameters should be considered when developing a high-impact biomarker for the neurological or psychiatric disorders.

 

ALAN BREIER, Session Chair

Vice President for Medical and Chief Medical Officer

Eli Lilly and Company

9:30 a.m.

What Impact Will the Genomics Field Have on the Immediate or the Near-Term Development of Biomarkers for Nervous System Diseases?

 

ALLEN ROSES

Senior Vice President

GlaxoSmithKline



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement